A registration form for patients who wish to enroll in the Vivitrol2gether program for case managers. This form contains all patient information, insurance information, entitled to a co-paying insurance program, prescription information and all the necessary signatures for patients and health care providers. (HCP can help the patient by working with the patient to complete the form.) IMPORTANT: The registration and participation of health care providers at the provider Locator is voluntary and free and, with the specific information of the provider in the provider`s locator, is based exclusively on the responses of health care providers. Inclusion in the Locator Provider does not involve any recommendation, recommendation or approval by Alkermes, Inc. We recommend that you search for each provider`s registration information, qualifications and experience before confirming an appointment. Alkermes is responsible to you or anyone for any decision or action you take by trusting this information. Use the supplier`s Locator tool below to find a doctor near you who can discuss vivitrol. If you are a health professional and would like to be listed as a provider, please download the form. Pregnancy/care: May cause extrapyramidae and/or withdrawal symptoms in nenates exposed in the third trimester.
Tell patients to tell their doctor about a known or suspected pregnancy. Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ARISTADA INITIO and/or ARISTADA during pregnancy. Aripiprazole is present in breast milk. The benefits of breastfeeding should be taken into account, along with the mother`s clinical needs in ARISTADA INITIO and/or ARISTADA and the potential adverse effects of ARISTADA INITIO and/or ARISTADA or the underlying maternal disease on the child. Note on Forward-Looking Statements Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to declarations, the entity`s expectations of its activities, plans and prospects, including its plans to develop the VIVITROL and ARISTADA supplier network, as well as its ability to support uninterrupted access to its medicines through other means. The Company cautions that forward-looking statements are inherently uncertain.